Aurobindo Pharma informs about updates

30 Sep 2023 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that The United States Food and Drug Administration (US FDA) inspected Unit VI - B, a Formulation manufacturing facility of the Company, situated at Chitkul Village, Patancheru Mandal, Sangareddy District, Telangana, from September 22 to September 29, 2023. At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature. The company will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest. The company will keep the stock exchanges further informed if there is any material information relating to the above in the future.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1172.30 -7.95 (-0.67%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×